A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Aβ-induced biomarker abnormality on cultured fibroblasts

@article{Khan2009ACM,
  title={A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Aβ-induced biomarker abnormality on cultured fibroblasts},
  author={Tapan K Khan and Thomas J. Nelson and Vishal A. Verma and Paul A Wender and Daniel L. Alkon},
  journal={Neurobiology of Disease},
  year={2009},
  volume={34},
  pages={332-339}
}
PKC signaling is critical for the non-toxic degradation of amyloid precursor protein (APP) and inhibition of GSK3beta, which controls phosphorylation of tau protein in Alzheimer's disease (AD). Thus the misregulation of PKC signaling could contribute to the origins of AD. Bryostatin, a potent PKC modulator, has the potential to ameliorate both the neurodegeneration and the recent memory loss associated with AD. As reported herein bryostatin and a potent synthetic analog (picolog) are found to… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 25 CITATIONS

Inhibition of PKCδ reduces amyloid-β levels and reverses Alzheimer disease phenotypes

  • The Journal of experimental medicine
  • 2018
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED